HealthTech 250 - 2026

Explore the HealthTech 250 list of top early-stage digital health startups to watch in 2026 — with industry trends, funding data, partnership signals, and global insights for investors and strategic partners.

HealthTech 250: A decision-grade shortlist of digital health ventures—built from evidence, not hype

An evidence-led shortlist of digital health ventures—built for faster shortlisting, benchmarking, and partner scouting.

The 2026 HealthTech 250 identifies high-momentum ventures using a transparent, signal-based methodology across funding, commercial partnerships, and evidence.

Download the 2026 HealthTech 250

Access the full intelligence layer in HealthTech Alpha

HealthTech 250 2026_Vertical

Digital health companies tracked

~1.5 billion

Data Points Analyzed

$1.6 billion

Raised by HT250 Ventures in 2025

Strategic Partnerships

What you get in the HealthTech 250 (2026) Download

The HealthTech 250 early-stage digital health startups list is organized in five XLSX lists designed for quick shortlisting, benchmarking, and outreach planning

United States

Top early-stage digital health ventures headquartered in the US, including top-funded deals such as Function Health ($298M).

Download xlsx

Asia Pacific

Digital health innovators across Singapore, India, Japan, and Australia driving telehealth, diagnostics, and AI-powered care delivery.

Download xlsx

Europe

Leading early-stage startups from the UK, France, Germany, Nordics, and Southern Europe building the next generation of health infrastructure.

Download xlsx

Rest of the World

High-potential ventures from Israel, Africa, Latin America, and the Middle East addressing healthcare access and diagnostic gaps.

Download xlsx

Top Clusters

The 3 leading innovation clusters across the HealthTech 250, with key trends, representative ventures, and average funding data.

Download xlsx

Get Access To All Data

Contact us to access the full HealthTech 250 dataset and the complete HealthTech Alpha platform.

Contact Us

Want the full universe beyond the HT250? HealthTech Alpha lets you expand the shortlist into a complete market map.

Download the 2026 HealthTech 250 Lists. The lists available include: 2026 HealthTech 250 - Top Digital Health Startups in United States 2026 HealthTech 250 - Top Digital Health Startups in Europe 2026 HealthTech 250 - Top Digital Health Startups in Asia Pacific 2026 HealthTech 250 - Top Digital Health Startups in Rest of the World 2026 HealthTech 250 - Key Clusters

Complete the form to access the lists aligned with your interest.

What the 2026 HealthTech 250 is Signalling

Three shifts stand out in this year’s selection.

Resilience is the new moat

The most credible ventures are showing durability across capital, commercial traction, and evidence—not just fundraising.

Evidence signals are back in focus

Clinical validation and real-world adoption are increasingly differentiators as buyers tighten procurement standards.

Infrastructure is quietly winning

Enablers—workflow, data, and distribution layers—are scaling alongside care delivery and condition-led solutions.

HealthTech 250 is the Shortlist. HealthTech Alpha is the Engine

The HealthTech 250 is designed for fast signal capture. HealthTech Alpha is what teams use when they need repeatable, board-ready intelligence at scale.

Expand Beyond 250

Build market maps from the full venture universe and filter by theme, geography, stage, and signal strength.

Validate faster

Compare ventures using evidence, partnerships, funding momentum, and competitive context.

Operationalize scouting

Export shortlists, track momentum, and create repeatable workflows for BD, strategy, and investment teams.

Request a Demo

Purpose & Scope

Objective
Identify leading early-stage digital health ventures demonstrating forward-looking momentum.
Intended Audience
Investors, Corporate Strategy, Pharma BD, Health Systems, Corporate Digital Health.
Geographic Scope
Global
Sector Scope
Digital Health innovation only iaw the HealthTech Alpha Digital Health taxonomy.
Exclusions
Biotech (pure drug discovery), non-digital devices, acquired ventures.

Data Sources & Signals

Data Source: HealthTech Alpha

Platform Coverage
Structured AI-powered Digital Health intelligence.
Companies Covered
50,000+
Investors Covered
16,000+
Corporates Covered
15,000+
Update Frequency
Real-time structured refresh.

Timeframe of Analysis

Funding Signals
Jan 2023 – Dec 2025
Partnership Signals
Jan 2023 – Dec 2025
Evidence Signals
Jan 2023 – Dec 2025
Snapshot Date
1-Feb-26

Definitions

Early Stage
Pre-Seed, Seed, Series A
Growth Stage
Series B–C
Late Stage
Series D+
Evidence Signal™
Structured measure of validation and regulatory progress.
Alpha Score
Composite maturity metric.

Scoring and Selection Process

Selection Framework (High-Level)

Quantitative Signals
Funding velocity, partnership density, evidence indicators.
Momentum Criteria
Recent raise or partnership, signal acceleration.
Qualitative Review
Analyst validation layer.
Exclusions
Acquired, inactive, insufficient transparency.

How to Use This Dataset

Deal Sourcing
Identify high-momentum ventures.
Competitive Benchmarking
Compare portfolio exposure.
M&A Radar
Monitor scale-ready targets.
Corporate Innovation
Identify validated partners.

Universe Definition

Incorporation Window
2021 – Present
Funding Stage Eligibility
Pre-Seed, Seed, Series A
Funding Stage Exclusion
Series B and later excluded
Venture Type
Digital Health ventures only

Stage 1 – Waterfall Filtering

Incorporation Date Filter
Between 1 January 2021 and snapshot date
Funding Stage Filter
No higher than Series A
Active Status
Must not be acquired or inactive
Data Sufficiency
Minimum structured signal coverage required

Stage 2 – Weighted Analysis & Geography Normalization

Purpose
Rank eligible ventures using composite weighted scoring.
Geography Normalization
Percentile benchmarking within comparable regions.
Weighted Metrics Framework
Metric Weight Description
2025 Relevance 25% Alignment with top trending Digital Health themes of 2025.
Alpha Score 15% Proprietary composite maturity assessment.
Clinical Evidence Signal 15% Assessment of validation and regulatory progress.
Funding Value Percentile 10% Capital raised percentile relative to stage and geography.
Funding Velocity 10% Speed of capital accumulation since incorporation.
Partnership Signal 10% Measured ecosystem engagement activity.
Health Check 15% Composite structural robustness indicator.

Adjustments vs Previous Edition

Weighting Update
Weighting matrices moderately refined compared to prior editions.
Rationale
Reflect evolving ecosystem dynamics and 2025 thematic shifts.

Scoring Outcome

Composite Score
Weighted aggregate of all Stage 2 metrics.
Final Selection
Top early-stage ventures ranked by normalized composite score.

Important Notes

Not Investment Advice
This ranking does not constitute investment recommendation.
Data Limitation
Based on structured disclosed data as of snapshot date.

FAQs

What exactly am I downloading?
A set of five XLSX lists: US, Europe, Asia-Pacific, Rest of World, and Top Clusters—each designed for rapid shortlisting and benchmarking.
What does “HealthTech 250” mean?
A curated selection of digital health ventures identified using a signal-based approach combining funding momentum, partnerships, and evidence.
What ventures are eligible?
The 2026 edition focuses on ventures incorporated in 2021 or later, with a strong emphasis on Series A and below.
How current is the data?
This release is a snapshot as of 1 Feb 2026. HealthTech Alpha enables ongoing refresh as signals change.
Is this investment advice?
No. The HealthTech 250 is an intelligence product for market understanding and benchmarking. It is not investment advice.
What’s the difference between the HT250 and HealthTech Alpha?
HT250 is a shortlist. HealthTech Alpha provides the full dataset + filters + workflow tools to scout, compare, and track ventures continuously.

Who Is It For?

Intended Audience
Investors, Corporate Strategy, Pharma BD, Health Systems, and Corporate Digital Health teams.
Primary Use Cases
Rapid shortlisting, benchmarking, and ongoing market tracking of early-stage digital health ventures.

Clusters & Therapeutic Areas

The cohort reflects a balance between disease-specific innovation and cross-therapeutic platforms, with a substantial share of startups operating in a disease-agnostic capacity. Among targeted areas, Oncology leads (16%), followed by Women’s Health (8%) and Mental Health (6%), with Cardiovascular and Wellness each at 5%. From a solution perspective, Health Management Solutions (24%) dominate, followed by Medical Diagnostics (16%) and Research Solutions (15%). Smaller but relevant clusters include Patient Solutions (8%), Wellness (7%), and Telemedicine (6%), reflecting a shift toward outcome-driven, infrastructure-oriented models.

Leading Digital Health Categories

The HealthTech 250 spans a broad range of digital health categories, with strong representation in health management solutions, diagnostics, and research. Compared with prior years, the 2026 cohort shows a clear shift toward ventures that integrate directly into clinical workflows or enable measurable operational improvements for healthcare providers, payers, and life sciences companies.

Therapeutic Area Distribution

From a therapeutic perspective, the 2026 cohort is led by oncology, women’s health, mental health, and cardiometabolic conditions. These areas combine large patient populations with clear unmet needs and strong commercial interest, making them attractive for both investors and strategic partners. The distribution reflects a broader industry trend toward condition-specific solutions that demonstrate clinical impact and economic value.

Funding Landscape

The cohort raised approximately USD 1.5--1.6 billion with an average deal size of USD 26.3 million. As of January 2026, the cohort maintains a 96% survival rate. Stand-out rounds include Function Health ($298M), Profluent ($106M), Paradigm ($78M), Nourish ($70M), and CertifyOS ($40M).

HT250 Aggregate Funding ($M)

Commercial Traction, Partnerships, and Clinical Evidence

1,001

Total Partnerships

141

New Partnerships in 2025

3,176

Publications

109

Clinical Trials

95

Regulatory Approvals

10

Acquisitions

Partnership Activity Across the Cohort

Partnerships continue to serve as a leading indicator of commercial traction across the HealthTech 250. In 2026, the cohort recorded over a thousand collaborations with pharmaceutical companies, health systems, insurers, and technology providers, reflecting strong demand for solutions that can integrate into real-world care pathways. Rather than experimental pilots, many of these partnerships focus on scaled deployments tied to measurable clinical or operational outcomes.

Clinical Trials and Regulatory Milestones

Clinical validation and regulatory progress remain critical signals of venture maturity. Across the 2026 cohort, startups have collectively initiated thousands of publications, clinical studies, and regulatory submissions, underscoring a shift toward evidence-backed solutions. This growing emphasis on trials, approvals, and real-world data reflects a market where procurement decisions increasingly depend on proven impact rather than early-stage promises.

Explore all HealthTech 250 Analyses